MicroRNA 3679 (miR-3679)

MicroRNA 3679 (miR-3679) is a short, non-coding RNA classified as a microRNA and transcribed as part of a primary transcript that is processed through the canonical microRNA biogenesis pathway (Drosha and Dicer), resulting in a mature miRNA incorporated into the RNA-induced silencing complex (RISC)[1][4]. miR-3679 and its mature form, miR-3679-3p, mediate post-transcriptional regulation by binding to partially complementary mRNA targets, leading to translational inhibition or target mRNA degradation. Genetic variants within the MIR3679 locus are associated with differences in bone mineral density, and manipulation of miR-3679-3p in human osteoblasts influences matrix mineralization, indicating a functional role in bone metabolism[2]. MIR3679 is also linked in disease association studies to lung non-small cell carcinoma and arrhythmogenic right ventricular cardiomyopathy, but mechanistic roles beyond those established for microRNAs in general remain to be defined for this specific miRNA[1]. Therapies directed at miR-3679 would likely take the form of oligonucleotide inhibitors or mimics but no approved or established interacting drugs are currently known.

Other names

MIR3679hsa-mir-3679mir-3679miR-3679-3p

Not applicable for direct drug targeting, as microRNAs themselves are targets for inhibitors/mimics (e.g., antisense oligonucleotides, miRNA mimics)